AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15807808 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneometer CM-B (CM820)
Number of subjects: 53
Study 15807808 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneometer CM-C (CM810)
Number of subjects: 53
Study 12204802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (A10)
Number of subjects: 391
Study 12204802 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day (S20)
Number of subjects: 391
Study 10344043 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 88
Study 10344043 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg
Number of subjects: 88
Study 10344043 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study 7661269 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (immediate full hyperextension)
Number of subjects: 174
Study 7661269 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (control, no immediate full hyperextension)
Number of subjects: 174
Study 8452322 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg per day
Number of subjects: 94
Study 8452322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3539796 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (acute oral administration)
Number of subjects: 9
Study 3539796 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (1 week treatment)
Number of subjects: 9
Study 3539796 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (6 weeks treatment)
Number of subjects: 9
Study 3539796 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (withdrawal of treatment)
Number of subjects: 9
Study 3539796 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (ambulatory intra‐arterial data)
Number of subjects: 9
Study 3539796 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 9
Study 29656273 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation mediated assessment
Number of subjects: 59
Study 29656273 — intervention group
Group type: COMPARATOR
Intervention: Conventional in‐person method
Number of subjects: 59
Study 27471837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat
Number of subjects: 47
Study 27471837 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 47
Study 23603054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 115
Study 22672214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser photocoagulation
Number of subjects: 80
Study 22672214 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin plus antiseptic cream
Number of subjects: 80
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with perpetrating forced sex
Number of subjects: 1499
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Earning income for less than 12 months a year
Number of subjects: 1499
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting the wine shop with friends
Number of subjects: 1499
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: STD symptoms
Number of subjects: 1499
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration of physical violence
Number of subjects: 1499
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 1499
Study 20692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Having 3 or more close friends
Number of subjects: 1499
Study 18446692 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow escalation of rivastigmine
Number of subjects: 429
Study 18446692 — intervention group
Group type: COMPARATOR
Intervention: Fast escalation of rivastigmine
Number of subjects: 429
Study 15695147 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 0
Study 15695147 — intervention group
Group type: COMPARATOR
Intervention: Co-morbidities (diabetes and coronary artery disease)
Number of subjects: 0
Study 12881334 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster biometry
Number of subjects: 100
Study 12881334 — intervention group
Group type: COMPARATOR
Intervention: Applanation ultrasonography
Number of subjects: 100
Study 9788519 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimen ratio of 0.5
Number of subjects: 6
Study 9788519 — intervention group
Group type: COMPARATOR
Intervention: Specimen ratio evaluation in a water dilution study
Number of subjects: 6
Study 7972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated small bowel volume below 77 cm3
Number of subjects: 203
Study 7972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated small bowel volume over 328 cm3
Number of subjects: 203
Study 7972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anterior resection
Number of subjects: 203
Study 7972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection
Number of subjects: 203
Study 7972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall small bowel obstruction
Number of subjects: 203
Study 2743665 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion machine
Number of subjects: 50
Study 2743665 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 50
Study 4560057 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan with a peripheral decarboxylase inhibitor
Number of subjects: 10
Study 4560057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31213409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema children
Number of subjects: 6
Study 31213409 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 6
Study 31204115 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (paclitaxel and iopromide)
Number of subjects: 208
Study 31204115 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 208
Study 28860894 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mL of 370 mgI/mL iodinated contrast media at a flow rate of 3.5 mL/s
Number of subjects: 104
Study 28860894 — intervention group
Group type: COMPARATOR
Intervention: 40 mL of 370 mgI/mL iodinated contrast media at a flow rate of 5 mL/s
Number of subjects: 104
Study 26364081 — intervention group
Group type: COMPARATOR
Intervention: Natural Cycle (NC FET group)
Number of subjects: 410
Study 26364081 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG FET group (hormonally stimulated cycle)
Number of subjects: 410
Study 23127578 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Module (LM, n=47)
Number of subjects: 87
Study 23127578 — intervention group
Group type: COMPARATOR
Intervention: Sham Module (SM, n=40)
Number of subjects: 87
Study 21559859 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (not specified in detail)
Number of subjects: 182
Study 18076751 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-incision cholecystectomy (SIC)
Number of subjects: 257
Study 18076751 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 257
Study 18076751 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional open technique (conversion from SIC or LC)
Number of subjects: 257
Study 16563715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of salbutamol
Number of subjects: 101
Study 16563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (after 6 and 12 weeks of therapy)
Number of subjects: 101
Study 16563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophilic inflammation (measured by serum concentration of myeloperoxidase)
Number of subjects: 101
Study 16563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical severity indicators and blood markers (including daily PEF variation, rescue bronchodilator use, severity of asthmatic symptoms, blood eosinophil count, serum eosinophilic cationic protein, and eosinophilic protein X concentrations)
Number of subjects: 101
Study 14626623 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practices in health promotion
Number of subjects: 0
Study 10709815 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line visual analysis during surgery
Number of subjects: 104
Study 10709815 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-line visual analysis in laboratory
Number of subjects: 104
Study 10709815 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer analysis
Number of subjects: 104
Study 10709815 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis for SEF variability and 8-15 Hz power variability and asymmetry
Number of subjects: 104
Study 9519501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg o.d.
Number of subjects: 129
Study 9519501 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg o.d.
Number of subjects: 129
Study 8480901 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Fentanyl
Number of subjects: 60
Study 8480901 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 8480901 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 60
Study 3481149 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz ray therapy
Number of subjects: 0
Study 30158217 — intervention group
Group type: EXPERIMENTAL
Intervention: PrenaBelt
Number of subjects: 20
Study 30158217 — intervention group
Group type: COMPARATOR
Intervention: Sham-PrenaBelt
Number of subjects: 20
Study 27573600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (ALI) 75/150mg every 2 weeks (Q2W)
Number of subjects: 4629
Study 27573600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (ALI) 150mg Q2W
Number of subjects: 4629
Study 27573600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (ALI)
Number of subjects: 4629
Study 25569680 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley balloon standard placement
Number of subjects: 79
Study 25569680 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley balloon immediate removal
Number of subjects: 79
Study 25569680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard placement)
Number of subjects: 79
Study 23546632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablet (FZHYT)
Number of subjects: 180
Study 23546632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 20887348 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting ß2-agonist and inhaled glucocorticoid (fluticasone propionate) for 3 months (group 2)
Number of subjects: 40
Study 20887348 — intervention group
Group type: COMPARATOR
Intervention: Long-acting ß2-agonist (salmeterol) for 3 months (group 1)
Number of subjects: 40
Study 18424594 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alpha-glycerophosphocholine (L-alpha) added to vegetarian lasagna
Number of subjects: 13
Study 18424594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (100 mg) added to vegetarian lasagna
Number of subjects: 13
Study 16382035 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole at 15 mg/kg/day plus dexamethasone for 8 days
Number of subjects: 36
Study 16382035 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole at 30 mg/kg/day plus dexamethasone for 8 days
Number of subjects: 36
Study 16382035 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (any dose)
Number of subjects: 36
Study 12794555 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle exchange program (NEP)
Number of subjects: 600
Study 12794555 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy Sales (training in how to purchase needles and syringes)
Number of subjects: 600
Study 10391534 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) with 0.625 mg/day of conjugated equine estrogen (CEE) or 50 microg/day of 17‐beta‐Estradiol in transdermal therapeutic systems (TTS), plus 5 mg/day of medroxyprogesterone acetate for those with natural menopause for the last 12 days of therapy.
Number of subjects: 154
Study 10391534 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated) for surgical menopause (n=77)
Number of subjects: 154
Study 10391534 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated) for spontaneous menopause (n=53)
Number of subjects: 154
Study 8874325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (IFN alpha 2b) treatment
Number of subjects: 280
Study 8874325 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 280
Study 2005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Occucoat (2% hydroxypropylmethyl‐cellulose) removed from the anterior chamber
Number of subjects: 114
Study 2005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Occucoat (2% hydroxypropylmethyl‐cellulose) retained
Number of subjects: 114
Study 2005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (sodium hyaluronate‐chondroitin sulfate) removed
Number of subjects: 114
Study 2005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (sodium hyaluronate‐chondroitin sulfate) retained
Number of subjects: 114
Study 2005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate) removed
Number of subjects: 114
Study 6213195 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (2.0 g) with 1.0 g probenecid
Number of subjects: 120
Study 6213195 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 X 10(6) U) with 1.0 g probenecid
Number of subjects: 120
Study 31607467 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous improvement strategies related to sexual health in intervention clusters
Number of subjects: 34878
Study 31607467 — intervention group
Group type: COMPARATOR
Intervention: Usual care in control clusters
Number of subjects: 34878
Study 29954736 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 357
Study 29954736 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and text message reminders
Number of subjects: 357
Study 29954736 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and mailed sunscreen
Number of subjects: 357
Study 29954736 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, text message reminders, and mailed sunscreen
Number of subjects: 357
Study 26328620 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing combined with Standard Care (MISC)
Number of subjects: 37
Study 26328620 — intervention group
Group type: COMPARATOR
Intervention: Standard Care only (SC)
Number of subjects: 37
Study 25112083 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at eight-neck-occiput points (Neck 1-4 points, Occiput 1-4 points), treatment once a day for 4 weeks, 5 treatments a week, using dense-dispersion wave for 30 minutes.
Number of subjects: 72
Study 25112083 — intervention group
Group type: COMPARATOR
Intervention: Routine acupoints (Lianquan (CV 23), Futu (LI 18), Tongli (HT 5), Hegu (LI 4), and others), treatment once a day for 4 weeks, 5 treatments a week, using dense-dispersion wave for 30 minutes.
Number of subjects: 72
Study 20434175 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 41
Study 20434175 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 41
Study 19593220 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bat (LB = 9.6 oz)
Number of subjects: 19
Study 19593220 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Bat (NB = 31.5 oz)
Number of subjects: 19
Study 19593220 — intervention group
Group type: COMPARATOR
Intervention: Heavy Bat (HB = 55.2 oz)
Number of subjects: 19
Study 16430409 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 45
Study 16430409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed Tracheal Tube (TT)
Number of subjects: 45
Study 16430409 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed Tracheal Tube (TT)
Number of subjects: 45
Study 12777270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.)
Number of subjects: 36
Study 12777270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10694522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of atrial septal defects under echocardiographic guidance without fluoroscopy
Number of subjects: 22
Study 10694522 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure (control group)
Number of subjects: 22
Study 9176846 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prednisone regimens
Number of subjects: 389
Study 9176846 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial responders (complete remission)
Number of subjects: 389
Study 9176846 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial relapsers (frequent and infrequent)
Number of subjects: 389
Study 9176846 — intervention group
Group type: EXPERIMENTAL
Intervention: Unremitting proteinuria during the initial 8 weeks of treatment
Number of subjects: 389
Study 9176846 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued proteinuria during the initial 8 weeks
Number of subjects: 389
Study 9176846 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcome
Number of subjects: 389
Study 1585795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) with Cimetidine (CIM)
Number of subjects: 8
Study 1585795 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC) without Cimetidine (CIM)
Number of subjects: 8
Study 3898911 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine-prilocaine cream (EMLA) applied for 20 min or longer
Number of subjects: 110
Study 3898911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 30203076 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette use
Number of subjects: 48
Study 30203076 — intervention group
Group type: EXPERIMENTAL
Intervention: No product use
Number of subjects: 48
Study 30203076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cigarette use
Number of subjects: 48
Study 30203076 — intervention group
Group type: COMPARATOR
Intervention: Dual use
Number of subjects: 48
Study 28700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (1-8)
Number of subjects: 243
Study 28700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (1-7)
Number of subjects: 243
Study 28700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyp3-bradykinin (1-7)
Number of subjects: 243
Study 28700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 243
Study 28700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyp3-bradykinin (1-8) in losartan group
Number of subjects: 243
Study 25592314 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based weight management intervention targeting diet and physical activity plus usual care
Number of subjects: 108
Study 25592314 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 23595264 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based and community partnered obesity intervention
Number of subjects: 0
Study 22042116 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol and intrapleural saline solution (Group A)
Number of subjects: 24
Study 22042116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone and intrapleural 0.33% ropivacaine (Group B)
Number of subjects: 24
Study 22042116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone and intrapleural 0.5% ropivacaine (Group C)
Number of subjects: 24
Study 20024764 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to prevent HIV transmission
Number of subjects: 116
Study 16686840 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT (photochemical treatment with amotosalen HCl and ultraviolet A light)
Number of subjects: 32
Study 16686840 — intervention group
Group type: COMPARATOR
Intervention: Reference (untreated apheresis PLTs)
Number of subjects: 32
Study 16686840 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 32
Study 16686840 — intervention group
Group type: COMPARATOR
Intervention: Reference
Number of subjects: 32
Study 15043516 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg/day)
Number of subjects: 45
Study 15043516 — intervention group
Group type: COMPARATOR
Intervention: Control (dyspeptic patients)
Number of subjects: 45
Study 11092108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg once daily
Number of subjects: 198
Study 11092108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol plus nifedipine 20 mg twice daily
Number of subjects: 198
Study 11092108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol plus amlodipine 5 mg once daily
Number of subjects: 198
Study 9557088 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-hour hemodialysis
Number of subjects: 23
Study 9557088 — intervention group
Group type: COMPARATOR
Intervention: Chronic uremic patients (pre-dialysis)
Number of subjects: 23
Study 8454139 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 200
Study 8454139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaCl solution
Number of subjects: 200
Study 8454139 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glucose/water solution
Number of subjects: 200
Study 8454139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure alcohol
Number of subjects: 200
Study 3749811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 87
Study 3749811 — intervention group
Group type: COMPARATOR
Intervention: High-dose liquid antacid
Number of subjects: 87
Study 3749811 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal ulcer (subgroup)
Number of subjects: 87
Study 3749811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepyloric ulcer (subgroup)
Number of subjects: 87
Study 29356271 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative serum (Matricium®) applied twice daily for 2 months after fractional laser procedure
Number of subjects: 0
Study 29356271 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 2 months after fractional laser procedure
Number of subjects: 0